NCT06052033Recruiting
Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
The Effect of 5-aminolaevulinic Acid Photodynamic Therapy Versus C02 Laser in the Treatment of Persistent Cervical Low-grade Squamous Intraepithelial Lesions With High-risk HPV Infection:A Non-randomized Controlled Trail Study
Source: ClinicalTrials.gov · Last updated 13 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Non-RCT clinical trial comparing 5-ALA photodynamic therapy and CO2 laser for persistent high-risk HPV-related low-grade cervical lesions.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 18 Sept 2023
- Start date
- 11 Sept 2023
- Primary completion date
- 10 Aug 2024
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical University
- Diseases
- Cervical cancer
- NCT number
- NCT06052033
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 11 Sept 2023 to the primary completion date, 10 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant endometrial cancer, ovarian cancer, and other reproductive tract tumors.
- Using drugs such as immunosuppressants, antiviral agents, and glucocorticoids.
Other illness
- HR-HPV persistent infection.
- Complicated with abnormal heart, liver, and kidney functions, immune dysfunction, or immune system diseases such as systemic lupus erythematosus (SLE).
- Diabetes patients with uncontrolled blood sugar.
Other
- A total hysterectomy has been performed.
- Pregnant and lactating women.
- Acute reproductive tract inflammation.
- Patients who do not receive full treatment and follow-up.
- Those who fail to sign the informed consent form.
Who the study is looking for
- Aged 18-65 years old with a history of sexual activity.
- Subclinical infected individuals who have been confirmed as HR-HPV positive (if there is the same positive type in the typing test) for more than 1 year using HPV typing test, HPV E6/E7 mRNA test, HPV DNA test, and cervical triple step diagnostic procedure (cytology colposcopy histopathology).
- Patients diagnosed with LSIL by pathological examination of cervical biopsy under colposcopy with an interval of more than 1 year.
- No fundamental diseases of important organs.
- Agree to receive treatment and/or follow-up according to regulations and sign an informed consent form.
- There has been no history of using other drugs related to HPV infection in the past 3 months.
Age in the registry: 18 years to 65 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| First Affiliated Hospital of Wenzhou Medical University Coordinator of this site? Confirm its status | Wenzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.